{{ variable.name }}
Stiripentol is a drug specially used to treat epilepsy. It mainly exerts its effect through a dual mechanism of action.
Common name:Stiripentol (Stiripentol)
Trade name:< /b>Diacomit
Other names:DIACOMIT capsule/oral suspension
For the treatment of epileptic seizures in patients with Dravet syndrome 2 years of age and older (needs to be used in combination with clobazam). There are no clinical data to support the use of monotherapy in Dravet syndrome.
Capsules:
250mg: No. 2 pink capsule, printed with "Diacomit" and "250mg"
500 mg: No. 0 white capsules, printed with "Diacomit" and "500mg"
Oral suspension:
250mg/pack or 500mg/pack with light pink fruit Flavored powder
Main ingredients
Active ingredient: stiripentol
Excipients: capsules contain gelatin, magnesium stearate, etc.; suspension contains aspartame (contains phenylalanine)
p>Standard dose:50mg/kg/day, taken in 2-3 times (maximum daily dose 3000mg)
Dosage method:< /b>
Capsules: swallow whole, with a glass of water during meals
Suspension: mix with 100mL of water and take immediately, then add 25mL of water to rinse
1. Missed dose: Take the dose immediately, skip if it is close to the next dose time
2. Vomiting: No need to take the next dose, take the next dose as originally planned
< b>3. Withdrawal of medication:Need to gradually reduce the dose (sudden withdrawal of medication may induce status epilepticus)
1. Taking time:Must be taken with meals to improve High absorption
2. Special handling:
Capsules cannot be broken or chewed
The suspension must be prepared for immediate use and must not be stored
3. Monitoring requirements :Check the blood routine before taking the drug and every 6 months
Pregnant women: It may cause fetal malformations, so the pros and cons need to be weighed (Pregnancy Registration No. 1-888-2 33-2334)
Lactation period:No relevant data, it is recommended to suspend breastfeeding
Children:Safety under 2 years old has not been established
Liver Renal insufficiency:Not recommended for moderate to severe patients
Common (≥10%): Drowsiness (67%), decreased appetite (45%), coma Disorders (27%), weight loss (27%)
Serious adverse reactions: Neutropenia (13%), thrombocytopenia (13%), QT interval prolongation
There are no absolute contraindications, but suspensions (containing phenylalanine) are contraindicated in patients with phenylketonuria
1. Increase the concentration: Make chlorine The concentration of Bazam and its metabolites increases 2-5 times (needs to reduce the dosage by 25%)
2. Contraindicated combinations: Strong CYP1A2/CYP3A4 inducers (such as rifampicin)
< b>3. Use with caution:CNS inhibitors (increased drowsiness)
1. Temperature:20-25℃ (short-term storage at 15-30℃ is allowed) )
2. Environment: Store in original packaging, protected from light and moisture
3. Period: Do not store for a long time after opening
French BIOCODEX company (1avenueBlaisePascal, 60000BEAUVAIS)